Your browser doesn't support javascript.
loading
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kß Inhibition in PTEN Loss Melanoma.
Peng, Weiyi; Williams, Leila J; Xu, Chunyu; Melendez, Brenda; McKenzie, Jodi A; Chen, Yuan; Jackson, Heather L; Voo, Kui S; Mbofung, Rina M; Leahey, Sara Elizabeth; Wang, Jian; Lizee, Gregory; Tawbi, Hussein A; Davies, Michael A; Hoos, Axel; Smothers, James; Srinivasan, Roopa; Paul, Elaine M; Yanamandra, Niranjan; Hwu, Patrick.
Afiliação
  • Peng W; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. phwu@mdanderson.org Niranjan.x.yanamandra@gsk.com Wpeng2@central.uh.edu.
  • Williams LJ; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Xu C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Melendez B; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • McKenzie JA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Chen Y; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jackson HL; Oncology R&D, Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Voo KS; Department of Oncology Research for Biologics and Immunotherapy Translation Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mbofung RM; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Leahey SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lizee G; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hoos A; Oncology R&D, Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Smothers J; Oncology R&D, Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Srinivasan R; Oncology R&D, Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Paul EM; Oncology R&D, Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Yanamandra N; Oncology R&D, Immuno-Oncology and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania. phwu@mdanderson.org Niranjan.x.yanamandra@gsk.com Wpeng2@central.uh.edu.
  • Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. phwu@mdanderson.org Niranjan.x.yanamandra@gsk.com Wpeng2@central.uh.edu.
Clin Cancer Res ; 25(21): 6406-6416, 2019 11 01.
Article em En | MEDLINE | ID: mdl-31371342
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-Idiotípicos / PTEN Fosfo-Hidrolase / Receptores OX40 / Melanoma Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-Idiotípicos / PTEN Fosfo-Hidrolase / Receptores OX40 / Melanoma Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article